Table 2. Incidence of ILD in gefitinib-treated patients (Forsythe and Faulkner, 2003b).

Gefitinib-treated patients	Incidence of ILD (death), %
Globally (n=∼92 750)	0.99 (0.36)
Japan marketed use (n=∼39 600)	1.86 (0.69)
Outside Japan (n=∼53 150)	0.34 (0.11)
US EAP (n =∼24 200)	0.39 (0.08)
Rest of world EAP (n=∼15 000)	0.38 (0.21)

EAP=expanded access programme; ILD=interstitial lung disease.